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Abstract Due of its superior soft tissue imaging
capabilities, magnetic resonance imaging (MRI) has
become the imaging modality of choice in many clinical
situations, as illustrated by the tremendous growth in
the number of MRIs performed over the past 2 decades.
In parallel, the number of patients who require pace-
makers or implantable cardiac defibrillators is increasing
as indications for these devices broaden and the
population ages. Taken together, these phenomena
present an important clinical issue, as MR scans are
generally contraindicated—except in urgent situations—
in patients who have implanted cardiovascular devices.
Potentially deleterious interactions between the magnetic
fields and radio frequency (RF) energy produced by MR
equipment and implantable devices have been identified,
including inhibition of pacing, asynchronous/high-rate
pacing, lead tip heating, and loss of capture. New
devices that incorporate technologies to improve MR
safety in patients with pacemakers have recently
received approval in Europe and are under evaluation
in the United States. Initial data from these devices
suggest that these devices are safe in the MRI
environment.
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1 Introduction
Increasingly, magnetic resonance imaging (MRI) has become
the imaging modality of choice across a broad range of
indications. It provides superior soft tissue contrast, is not
obstructed by bone, and provides a three-dimensional image
of anatomical structure that is valuable in guiding both
diagnosis and treatment without exposing patients to the risks
associated with ionizing radiation, invasive procedures, or
iodinated contrast agents. For these reasons, MRI is the
fastest-growing imaging modality and has become the
standard of care for the evaluation of disease and treatment
management across multiple therapeutic areas, including—
but not limited to—oncology, central nervous system and
musculoskeletal disorders, and, to an increasing extent,
cardiovascular disease. Based on United States data from
1993 to 2002, MRI procedures increased dramatically from
7.7 million to nearly 22 million [1]; the most recent data
suggest that there were 27.5 million procedures in 2007
(Fig. 1) [2]. Worldwide, approximately 60 million scans are
performed each year [3].
Parallel to the growth of MRI as the imaging modality of
choice in many clinical situations, the number of patients with
implantable cardiac devices, such as pacemakers and implant-
able cardiac defibrillators (ICDs), has been increasing steadily
as the population ages and indications and recommendations
for these devices expand. The rapid growth in MRI and the
increase in patients who require implantable cardiac devices
have led to a situation in which 50% to 75% of patients with
implanted devices will be indicated for MRI scans over the
lifetime of their device [1].One study found that during a 12-
month follow-up period, 17% of patients with pacemakers
required a diagnostic MRI [4].
Pacemakers and ICDs contain metal with variable ferro-
magnetic qualities, complex electrical systems, and ≥1 leads
W. Jung (*) :V. Zvereva :B. Hajredini : S. Jäckle
Department of Cardiology, Academic Teaching Hospital of the




J Interv Card Electrophysiol (2011) 32:213–219
DOI 10.1007/s10840-011-9610-0
implanted in the myocardium. The static main magnetic field,
radio frequency (RF) energy, and gradient magnetic fields
associated with MRI have the potential to interfere with
pacemaker function. For this reason, significant controversy
exists regarding the safety of MRI examination in patients
with implantable cardiac devices, particularly in light of the
increasing field strengths of clinical MRI scanners. In general,
the American Heart Association guidelines indicate that MRI
examination of nonpacemaker-dependent patients is discour-
aged, except in cases with a strong clinical indication and in
which the benefits clearly outweigh the risks [5]. Among
pacemaker-dependent patients and those with ICDs, MRI
examination is generally not recommended except under
highly compelling circumstances [5]. As a result of these
concerns, no implantable cardiovascular electronic devices
have United States Food and Drug Administration (US
FDA) approval or Centers for Medicare and Medicaid
Services coverage for use in the MRI environment, and
“Do not use MR imaging for patients who have an implanted
device” appears on product labels. Support for this contra-
indication came from several reports of lethal consequences
associated with MRI in patients with implanted pacemakers
[6–8]. This creates a significant problem in that annually
approximately 200,000 patients with devices may be denied
a scan due to the presence of an ICD [1, 9].
In light of the current controversy regarding the safety of
MRI scans in patients with pacemakers or ICDs, this review
focuses first on an evaluation of the potential risks of
scanning in this patient population, followed by an
examination of new technologies intended to reduce or
eliminate these concerns.
2 Risks of MRI in patients with pacemakers
There are a number of potential interactions between MRI
and components of pacing and defibrillation systems,
including the device, the lead (including abandoned leads),
and the system itself (Table 1) [1]. Variables affecting the
magnitude of risk are summarized in Table 2.
Static magnetic fields exert mechanical forces on
ferromagnetic components within the device [10], which
may rotate, dislodge, or accelerate ferromagnetic devices
toward the magnet, potentially resulting in serious patient
harm. Furthermore, static magnetic fields may result in
unpredictable magnetic sensor activation and reed-switch
closure, potentially resulting in reversion to asynchronous
pacing when the switch is closed or falsely classifying
electromagnetic interference as cardiac activity and inhibit-
Total MRI procedure volume in millions,
2000-2007, hospital and nonhospital sites
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Fig. 1 Total MRI procedure
volume in millions, 2000–2007,
hospital and nonhospital sites
[2]. Reprinted with permission
from AuntMinnie.com
Table 1 Potential effects of magnetic resonance imaging on
pacemakers [10]
Potential effects of MRI on pacemakers
(1) Static magnetic field
Mechanical forces on ferromagnetic components
Unpredictable magnetic sensor activation, reed-switch closure
Changes in electrocardiograms
(2) Modulated radio frequency field
Heating of cardiac tissue adjacent to lead electrodes
Possible induction of life-threatening arrhythmias (very rare)
Pacemaker reprogramming or reset
RF interactions with the device (over- and undersensing)
(3) Gradient magnetic field
Possible induction of life-threatening arrhythmias (unlikely in
bipolar mode)
Induced voltages on leads cause over- and undersensing
(4) Combined field effects
Alteration of device function because of electromagnetic
interference
Mechanical forces (vibration)
Electronic reset of device
Damage to pacemaker/implantable cardiac defibrillator and/or leads
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ing the need for pacing support when the switch is open
[10]. RF interactions with the device may result in
oversensing (resulting in high-rate pacing beyond the
pacemaker rate limit), undersensing, cardiac tissue heating
and thermal damage, pacemaker reset, and, in rare cases,
induction of life-threatening arrhythmias. Furthermore,
rapidly changing gradient magnetic fields have the potential
to induce voltages on leads that may cause oversensing and
undersensing. Combined field effects may result in com-
ponent failures, mechanical vibration, or device damage
[10]. The main risks to pacemakers in patients undergoing
MRI can be placed into three categories: (1) inhibition of
pacing, (2) asynchronous/high-rate pacing, and (3) lead tip
heating and loss of capture.
The potential effects of 0.5-T MRI on pacemakers were
initially evaluated by Lauck and colleagues [11] using a
phantom model with seven dual-chamber and two single-
chamber systems. Upon entering the static magnetic field,
the reed switch was activated followed by asynchronous
stimulation. The subsequent scan did not influence the
stimulation function or the pacemaker program, and the
event counter function remained intact. In pacemakers with
automatic mode switching to demand pacing or
programmed evaluation of the reed switch, triggering was
observed in the dual-chamber mode and inhibition was
observed in the single-chamber mode during the scan.
Changes in the pacemaker program or rapid pacing were
not observed. The authors concluded that pacemakers
should be programmed in the asynchronous mode during
the scan to avoid inhibition and trigger mechanisms. The
effects of 0.5-T MRI were also assessed in 32 patients (34
MRI examinations) with implanted pacemakers, with
measurements at baseline, immediately after MRI, and
3 months after MRI [12]. At this field strength, lead
impedance and sensing and stimulation thresholds were
unaltered by MRI; however, battery current and impedance
increased after the scan. Although battery voltage decreased
immediately after MRI, 3-month measurements indicated
that voltage recovered fully. Notably, temporary deactiva-
tion of the reed switch occurred in more than one-third of
patients (12 of 32).
The potential for inhibition of pacing is illustrated in
Fig. 2 and was demonstrated in a study conducted by
Mollerus and colleagues [13]. In this study 52
nonpacemaker-dependent patients with a total of 119 leads
underwent 59 MRI scans of any landmark, using standard
peak absorption rate settings for the scan. Devices were
Table 2 Potential variables affecting the magnitude of risks in
pacemaker/ICD patients undergoing MRI
(1) Pacemaker design
Ferromagnetic content
Switch design (reed vs. Hall)
Availability of dedicated modes for use during MRI
(2) Lead design and length
Lead geometry
Lead input filtering capacitance
(3) Blood flow at lead/tissue interface
(4) Presence of abandoned leads
(5) MRI scan duration
(6) Strength of RF field
(7) Isocenter of scan
(8) Type of imaging sequence
(9) Patient and device/lead position within scanner
(10) Type and extent of patient monitoring
Fig. 2 Potential for inhibition of pacing [26]
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programmed to single-chamber demand mode (VVI) or
dual-chamber demand mode (DDI) with a lower rate of
40 bpm. Pacing outputs and sensitivities were not changed
for the scan, and magnet mode was disabled. If an ICD was
present, therapy features were disabled. Telemetry and pulse
oximetry plethysmographic waveform were continuously
evaluated for ectopy (defined as ≥20 ectopic beats during the
entire scan) throughout the scans [13]. A total of seven
patients had significant ectopy observed either on telemetry
or from observation of the oxygen saturation plethysmo-
graphic waveform. No scans were associated with changes in
pacing thresholds; however, there were small decreases in
sensing amplitudes and pacing impedances [13].
Martin and colleagues [14] reported on a series of 54
nonpacemaker-dependent patients who underwent 62 MR
examinations using a 1.5-T MR system. Notably, the type
of MRI examination was not limited and included cardiac,
vascular, and general MRI studies using various whole-
body, averaged, specific absorption rates (SARs); nor was
the type of pacemaker present in the patient restricted.
Pacemakers were interrogated before and immediately after
MRI scanning, and patients were continuously monitored
during scanning. Although no adverse events occurred,
pacing threshold changes were observed in 40 (37%) of
leads, including ten that were judged clinically significant
and two that required a change in programmed output.
Martin and colleagues [14] conclude that “safety was
demonstrated in this series of patients”; however, it is
important to note that no patients underwent long-term
follow-up, a particular concern in patients who experienced
a significant change in pacing thresholds.
Electrical reset (e.g., restoration of the factory setting
with predefined synchronous pacing mode and parameters)
has been demonstrated to occur in patients with implanted
devices subjected to MRI. Reset is an emergency mode that
is a safety feature to guarantee at least minimal pacemaker
functionality in the event of battery voltage dips. In a
prospective study conducted by Sommer and colleagues
[15], nonpacemaker-dependent patients with an urgent need
for an MRI examination underwent a total of 115 MRI
examinations at 1.5-T. Pacemakers were reprogrammed
prior to MRI, such that if the heart rate was <60 bpm,
the asynchronous mode was used to reduce the risk for
MRI-induced inhibition; if the patient had a heart rate
of >60 bpm, the sense-only mode was programmed to
reduce the potential for MRI-induced competitive pacing
and potential proarrhythmia. Pacemakers were interro-
gated before and after the scan and after 3 months,
including measurement of the pacing capture threshold
and serum troponin I levels [15]. Although all MRI
examinations were completed safely, post-MRI interroga-
tion showed that electrical pacemaker reset occurred in
seven (6.1%) examinations. In all cases, the pacemaker
could be reprogrammed to the parameters used prior to the
MRI scan [15].
The potential for electrical reset presents a safety hazard for
two reasons. First, in cases in which a reset occurs
concomitant with an open reed switch, bradycardia/asystole
may occur in patients with low intrinsic heart rates as a result
of inhibition of pacemaker output by time-varying gradient
fields. Second, the default pacing mode may not necessarily
provide adequate functionality for certain patients [10].
The reed switches contained in most current pacemakers
are susceptible to the magnetic fields generated during
MRI. The state of the reed switch in various orientations
and positions in the magnetic fields of 0.5. 1.5, and 3.0 T
was evaluated by Luechinger and colleagues [16]. When
oriented parallel to magnetic fields, reed switches closed at
1.0±0.2 mT and opened at 0.7±0.2 mT. In low magnetic
fields (<50 mT) reed switches were closed, and in high
magnetic fields (>200 mT) reed switches opened in 50% of
orientations [16]. These data suggest that the position of the
reed switch may not be predictable in patients undergoing
MRI, a hypothesis supported by the fact that the reed
switch remained inactivated in 44.7% of patients in the
Sommer et al. study [15].
Heating results from power deposition by the RF
radiation used in MRI and is dependent on SAR, position
of the pacemaker lead loop in the RF coil, configuration of
lead, and the lead model [15, 17]. RF-induced tissue
damage is also a function of both temperature and exposure
time. The electrode-tissue boundary is particularly vulner-
able to heating, resulting in a potential risk for thermal
injury of the tissues adjacent to the electrode, deterioration
of the pacing thresholds, and atrial or ventricular perfora-
tion. In vitro, temperature increases of up to 63.1°C have
been seen at 1.5 T [18]; animal studies have demonstrated
increases of up to 20.4°C at 1.5 T and an SAR of 3.8 W/kg
[19]. Such changes in temperature have the potential to
cause serious harm to the patient as a result of loss of
pacemaker capture [20]. Pacemaker leads abandoned after
pulse generator removal present similar problems, regard-
less of whether they are capped or otherwise electrically
intact [10].
In the study conducted by Sommer and colleagues [15]
(summarized previously), cardiac troponins were increased
in four of 114 examinations; in one case these increases
were associated with a significant increase in pacing
capture threshold. Moreover, there were six pacing capture
threshold changes ≥1.0 V in 195 leads, and statistical
analysis showed that there was a significant increase in
pacing capture threshold from pre- to post-MRI. None of
these changes had clinically relevant effects (e.g., requiring
an increase in pacemaker output to ensure stimulation
within a sufficient safety margin) [15]. Of note, possible
long-term effects of scanning were identified, in that two
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cases of increased pacing capture threshold were not
detected until the 3-month follow-up [15]. The authors
speculate that scar tissue development around the lead tips,
as a result of RF-related thermal injury, was the cause of
these changes. Notably, this study was conducted with
significant precautions against RF-induced heating, includ-
ing limiting the SAR to <1.5 W/kg and excluding anatomic
regions with full coverage of the pacemaker lead loop,
including the thoracic spine, heart, and breasts. The total
active scan time was also limited to 30 min [15].
The results from the Sommer and Martin studies are at
odds with an earlier, small (40 patients) series published by
Mollerus and colleagues [21], in which no cases of troponin
elevations or changes in capture thresholds were observed.
It remains open to debate whether MRI scans will produce
sufficient tissue heating to cause enough myocardial cell
necrosis to result in cardiac biomarker release.
3 MRI-safe devices: features
As a result of the risks imposed by MRI in patients with
pacemakers and ICDs—and the increasing importance of
MRI as a diagnostic tool—considerable research has been
conducted to develop devices that are safe in this
environment. To improve the safety of these devices,
components have been redesigned and new features,
particularly lead design and geometry, have been incorpo-
rated into these systems.
Multiple features are required to improve the safety of
pacemakers and ICDs in the MRI environment, including
improved control of reed switch behavior, better protection
against electromagnetic interference leading to electrical reset,
dedicated MRI modes for specific patient populations, and—
perhaps most importantly—pacemaker leads with no or minor
RF-induced temperature increases. The SureScan™ pacing
system, which is approved in Europe and is under evaluation
in the United States, has incorporated many of these features
to improve safety during an MRI scan. These features include
changing the lead input-filtering capacitance to minimize the
energy induced on leads/discharged at the tip, replacement of
the reed switch with a Hall sensor, internal power supply
circuit protection, and a reduction in ferromagnetic compo-
nents (Table 3). The device provides dedicated modes with
clear steps to provide predictable pacemaker performance
during the scan and includes radiographic markers to
improve device identification.
4 MRI-safe devices: testing and clinical experience
At present, two systems “MRI-conditional” devices are
available, the Revo system (Medtronic) and the ProMRI
system (Biotronik). It is important to note that these
devices, although specifically designed for the MRI
environment, have their own set of limitations. For
example, the Revo system limits the static magnetic field
strength to 1.5 T, and the patient must be positioned within
the bore such that the isocenter is superior to the C1
vertebra and inferior to the T12 vertebra. The whole-body
averaged SAR must be ≤2.0 W/kg, and the head SAR must
be <3.2 W/kg. The ProMRI system requires that a field
strength of 1.5 T not be exceeded and has similar isocenter
limitations. Both devices recommend that proper patient
monitoring be provided during the MRI scan, including
visual and verbal contact with the patient, electrocardiog-
raphy, and pulse oximetry.
At present, there are no publicly available data on
completed or ongoing studies to confirm the MRI safety of
the ProMRI system. However, the EnRhythm MRI study
evaluated the Revo pacemaker and lead system designed to
minimize lead tip heating and provide a programmable
MRI pacing mode in a worldwide, prospective, random-
ized, controlled, unblinded clinical trial [3]. The study
enrolled patients with standard indications for a dual-
chamber pacemaker implantation; successfully implanted
patients were randomized in a 2:1 ratio to undergo MRI or
to have no MRI scan at 9 to 12 weeks after pacemaker
system implantation. At this time patients received 14
clinically relevant head and lumbar scan sequences per-
Table 3 New technologies incorporated in MR-conditional pacing systems
Change Potential benefit
Lead input filtering capacitance Minimize energy induced on leads/discharged at tip
Reed switch replaced by Hall sensor Control switch behavior
Internal power supply circuit protection Prevents energy induced on telemetry antenna from disrupting internal power supplies
Reduction in ferromagnetic components Decreases susceptibility to magnetic attraction
Dedicated modes for use during MRI Suspension of diagnostic data collection and atrial arrhythmia therapy
Lead geometry changes Reduce lead heating
Radiographic markers Allows identification of MRI-conditional devices
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formed on 1.5-T machines, maximizing gradient slew rate
and/or transmitted power up to an SAR of 2 W/kg (control
patients waited 1 h with no MRI). All patients were
evaluated before and 1 week and 1 month after the study
visit [3].
An initial report of this study was recently published [22].
At the time of the report, a total of 464 patients had been
implanted at multiple centers in the United States, Europe,
Canada, and the Middle East. There were no reports of MRI-
related complications or MRI-attributed sustained ventricular
arrhythmias, asystole episodes, or pacemaker malfunctions.
The system-related, complication-free rate was 91.7% (P<
0.001). At 1 month after the MRI visit, capture thresholds,
sensing amplitudes, and lead impedance were stable and
similar between MRI and control patients. In all cases
except one control ventricular lead, pacing capture
threshold increases were ≤0.5 V. Sensing amplitude
decreases of >50% (or to <1.5 mV in an atrial lead or
<5.0 mV in a ventricular lead), were observed for atrial
leads in 5.3% and 7.2% of MRI and control patients,
respectively, and for ventricular leads in 3.0% and. 5.1%
of MRI and control patients, respectively. No evidence
was found for clinical (bradycardia or tachycardia),
subclinical (pacemaker performance), or technical (pace-
maker or lead damage) adverse events observed in
patients receiving an MRI.
A second single-center, controlled, nonrandomized study
recently reported by Forleo and colleagues [23], provides a
direct safety and efficacy comparison between an MRI-
compatible pulse generator and lead system with conven-
tional dual-chamber pacing (DDD) implant outcomes.
Because the redesign of the system to be MRI-safe required
increased lead diameter and stiffness, implantation success
was also evaluated in this small study. In the study, 107
consecutive patients were implanted with either the MRI-
compatible device or a dual-chamber, active-fixation lead
non-MRI system. Data were collected at implant and during
postoperative follow-up through 12 months. The implanta-
tion success rate in both groups was 100%; the desired
values for pacing threshold, P- and R-wave amplitudes, and
impedance were obtained in all patients [23]. As expected,
given the increased diameter of MRI-safe leads, successful
cephalic vein access of both leads was slightly, though not
significantly, lower in patients who received MRI leads
(60.0%) compared with DDD patients (68.4%). Subclavian
vein puncture to place at least one lead was required in
40.0% of MRI patients and 31.6% of DDD patients.
Overall, there was no difference in procedure times.
Fluoroscopy time in the DDD group was shorter;
however, this difference did not reach statistical signif-
icance. There were no cases of high-threshold or
inadequate sensing. Importantly, there was no difference
between the two groups in the incidence of complica-
tions at implant; no chronic lead displacement, exit
block, sensing problem, lead conductor fracture, insula-
tion defect, or infections were observed during the
follow-up period. These data—while not indicative of
the performance of the system in the MRI environment—
indicate that the MRI-compatible system can be used safely
and effectively for cardiac pacing.
5 Conclusions
Although some studies suggest that with appropriate
precautions, MRI scans can be conducted safely in patients
with pacemakers or ICDs, it is apparent that MRI scans
have the potential to cause serious deleterious effects in this
patient population. Moreover, as noted by Gimbel in 2009,
only about 1500 scans have been reported on device
patients in the medical literature [24], and the vast majority
of these reports are from studies conducted at institutions
with significant expertise in MRI and electrophysiology [5].
Moreover, it is highly likely that the majority of adverse
events occurring during MRI scans of patients with pace-
makers or ICDs have gone unreported. These concerns are
also highlighted by an editorial, written by Faris and Shein
on behalf of the US FDA, that states “while the FDA
recognizes that there are pacemaker and ICD patients for
whom, on a case-by-case basis, the diagnostic benefit from
MRI outweighs the presumed risks, we believe that those
risks have not yet been characterized and mitigated
sufficiently to justify the routine use of MRI examination
in those populations” [25]. It is also worthwhile to note that
MRI technology is evolving with higher static magnetic
fields, faster gradient fields, and stronger RF fields. As
such, the majority of currently published data may not
reflect clinical reality in terms of the risks imposed by
newer MRI technologies.
The value of MRI in a broad range of patient
populations is indisputable and, as noted earlier, the
number of patients with indications for such scans is
likely to grow significantly in the future—there is
already a significant overlap between patients who
require pacemakers or ICDs and those who would ideally
undergo scanning. The availability of MRI-safe technol-
ogies reduces the concerns associated with MRI scanning
in patients with pacemakers and ICDs.
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